FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2114313621> ?p ?o ?g. }

• W2114313621 endingPage "2961" @default.
• W2114313621 startingPage "2947" @default.
• W2114313621 abstract "$('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); Hua Yang 1 , Harshani R. Lawrence 3 , Aslamuzzaman Kazi 1 , Harsukh Gevariya 1 , Ronil Patel 1 , Yunting Luo 3 , Uwe Rix 1 , 2 , 4 , Ernst Schonbrunn 1 , 2 , 4 , Nicholas J. Lawrence 1 , 2 , 4 , Said M. Sebti 1 , 2 , 4 1 Drug Discovery Department, University of South Florida, Tampa, FL, USA. 2 Chemical Biology and Molecular Medicine Program, University of South Florida, Tampa, FL, USA. 3 Chemical Biology Core, Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL, USA. 4 Departments of Molecular Medicine and Oncologic Sciences, University of South Florida, Tampa, FL, USA. Correspondence: Sa&#x00EF;d M. Sebti, e-mail: said.sebti@moffitt.org Conflict of Interests The Authors have no conflict of interests. Received : November 20, 2013&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0; Accepted : March 19, 2014&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0; Published : March 22, 2014 ABSTRACT Aurora A and JAK2 kinases are involved in cell division and tumor cell survival, respectively. Here we demonstrate that ectopic expression of Aurora A and JAK2 together is more effective than each alone at inducing non-transformed cells to grow in an anchorage-independent manner and to invade. Furthermore, siRNA silencing or pharmacological inhibition of Aurora A and JAK2 with Alisertib and Ruxolitinib, respectively, is more effective than blocking each kinase alone at suppressing anchorage-dependent and &#x2013;independent growth and invasion as well as at inducing apoptosis. Importantly, we have developed dual Aurora and JAK inhibitors, AJI-214 and AJI-100, which potently inhibit Aurora A, Aurora B and JAK2 in vitro. In human cancer cells, these dual inhibitors block the auto-phosphorylation of Aurora A (Thr-288) and the phosphorylation of the Aurora B substrate histone H3 (Ser-10) and the JAK2 substrate STAT3 (Tyr-705). Furthermore, AJI-214 and AJI-100 inhibit anchorage dependent and independent cell growth and invasion and induce G2/M cell cycle accumulation and apoptosis. Finally, AJI-100 caused regression of human tumor xenografts in mice. Taken together, our genetic and pharmacological studies indicate that targeting Aurora A and JAK2 together is a more effective approach than each kinase alone at inhibiting malignant transformation and warrant further advanced pre clinical investigations of dual Aurora A/JAK2 inhibitors as potential anti tumor agents." @default.
• W2114313621 created "2016-06-24" @default.
• W2114313621 creator A5005324140 @default.
• W2114313621 creator A5012452779 @default.
• W2114313621 creator A5023344713 @default.
• W2114313621 creator A5024223427 @default.
• W2114313621 creator A5027503793 @default.
• W2114313621 creator A5031144571 @default.
• W2114313621 creator A5056350826 @default.
• W2114313621 creator A5057921101 @default.
• W2114313621 creator A5065882417 @default.
• W2114313621 creator A5076875770 @default.
• W2114313621 date "2014-03-22" @default.
• W2114313621 modified "2023-09-27" @default.
• W2114313621 title "Dual Aurora A and JAK2 kinase blockade effectively suppresses malignant transformation" @default.
• W2114313621 cites W1485263743 @default.
• W2114313621 cites W1489022916 @default.
• W2114313621 cites W1548640328 @default.
• W2114313621 cites W1556655356 @default.
• W2114313621 cites W1970815499 @default.
• W2114313621 cites W1977924803 @default.
• W2114313621 cites W1980577287 @default.
• W2114313621 cites W1980612591 @default.
• W2114313621 cites W1990317973 @default.
• W2114313621 cites W1993075590 @default.
• W2114313621 cites W1997353566 @default.
• W2114313621 cites W2000767526 @default.
• W2114313621 cites W2002857443 @default.
• W2114313621 cites W2006240263 @default.
• W2114313621 cites W2006245826 @default.
• W2114313621 cites W2009114635 @default.
• W2114313621 cites W2011860226 @default.
• W2114313621 cites W2012828222 @default.
• W2114313621 cites W2018060537 @default.
• W2114313621 cites W2029335488 @default.
• W2114313621 cites W2038254125 @default.
• W2114313621 cites W2038619046 @default.
• W2114313621 cites W2043200077 @default.
• W2114313621 cites W2043394356 @default.
• W2114313621 cites W2044268362 @default.
• W2114313621 cites W2059575225 @default.
• W2114313621 cites W2060619702 @default.
• W2114313621 cites W2064261028 @default.
• W2114313621 cites W2066042119 @default.
• W2114313621 cites W2070308429 @default.
• W2114313621 cites W2071156666 @default.
• W2114313621 cites W2079645940 @default.
• W2114313621 cites W2095738224 @default.
• W2114313621 cites W2096491402 @default.
• W2114313621 cites W2109877587 @default.
• W2114313621 cites W2114220172 @default.
• W2114313621 cites W2121754704 @default.
• W2114313621 cites W2125257843 @default.
• W2114313621 cites W2126572395 @default.
• W2114313621 cites W2128553601 @default.
• W2114313621 cites W2131815304 @default.
• W2114313621 cites W2132039647 @default.
• W2114313621 cites W2139655719 @default.
• W2114313621 cites W2144806169 @default.
• W2114313621 cites W2147066734 @default.
• W2114313621 cites W2147306114 @default.
• W2114313621 cites W2152637502 @default.
• W2114313621 cites W2160475600 @default.
• W2114313621 cites W2330829715 @default.
• W2114313621 cites W2408845131 @default.
• W2114313621 cites W4252646692 @default.
• W2114313621 doi "https://doi.org/10.18632/oncotarget.1615" @default.
• W2114313621 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4102782" @default.
• W2114313621 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24930769" @default.
• W2114313621 hasPublicationYear "2014" @default.
• W2114313621 type Work @default.
• W2114313621 sameAs 2114313621 @default.
• W2114313621 citedByCount "19" @default.
• W2114313621 countsByYear W21143136212014 @default.
• W2114313621 countsByYear W21143136212015 @default.
• W2114313621 countsByYear W21143136212016 @default.
• W2114313621 countsByYear W21143136212017 @default.
• W2114313621 countsByYear W21143136212019 @default.
• W2114313621 countsByYear W21143136212020 @default.
• W2114313621 countsByYear W21143136212021 @default.
• W2114313621 crossrefType "journal-article" @default.
• W2114313621 hasAuthorship W2114313621A5005324140 @default.
• W2114313621 hasAuthorship W2114313621A5012452779 @default.
• W2114313621 hasAuthorship W2114313621A5023344713 @default.
• W2114313621 hasAuthorship W2114313621A5024223427 @default.
• W2114313621 hasAuthorship W2114313621A5027503793 @default.
• W2114313621 hasAuthorship W2114313621A5031144571 @default.
• W2114313621 hasAuthorship W2114313621A5056350826 @default.
• W2114313621 hasAuthorship W2114313621A5057921101 @default.
• W2114313621 hasAuthorship W2114313621A5065882417 @default.
• W2114313621 hasAuthorship W2114313621A5076875770 @default.
• W2114313621 hasBestOaLocation W21143136211 @default.
• W2114313621 hasConcept C104317684 @default.
• W2114313621 hasConcept C119056186 @default.
• W2114313621 hasConcept C121608353 @default.
• W2114313621 hasConcept C126322002 @default.
• W2114313621 hasConcept C184235292 @default.
• W2114313621 hasConcept C2780808130 @default.

• next